Wed, Jul 23, 2014, 9:49 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • enabeler enabeler Jan 11, 2013 7:08 PM Flag

    Zytiga (abiraterone) receives approval for early use in EU, JNJ+EXEL=$'s

    " The European Commission has approved use of Johnson & Johnson's prostate cancer drug earlier in treatment, making it available for more men, the company said Friday.
    Zytiga, known chemically as abiraterone, can now be given to men with advanced prostate cancer that hasn't responded to hormonal treatment and who have not yet had chemotherapy. Until now, the once-a-day pill was only approved in European Union countries for use in men whose prostate cancer had worsened during or after chemotherapy."

    The FDA has already given it's blessing to Zytiga's early use before chemo. Maybe we should check to see if any JNJ execs are buying EXEL shares? Or maybe JNJ execs are busy trying to keep EXEL's shares from getting too expensive (selective shorting). I'm with longfcel and betting that Comet 1 (combined abi/cabo treatment) gets terminated early due to positive median overall survivor stats.

    Have a nice weekend. The Euro Commission and FDA have now approved both abi and cabo....together they will blow away the cancer drug market and JNJ will have no choice but to either buy EXEL or share the billions in future revenues.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "....betting that Comet 1 (combined abi/cabo treatment) gets terminated early due to positive median overall survivor stats." There is a decent chance that Comet 1 will get an early termination. EXEL built a single interim analysis into the protocol so that in case the drug showed exceptional efficacy, the company, vis a vis its standing instructions to the Data Monitoring Committee, could terminate the trial early without jeopardizing the validity of the results.

    • $$$$

      "I'm with longfcel and betting that Comet 1 (combined abi/cabo treatment) gets terminated early due to positive median overall survivor stats."

      "The Euro Commission and FDA have now approved both abi and cabo...."

      Love yer enthusiasm, Enabler, but I suspect the Message Board Rumor-mill Police are going to hafta pay you a visit... even if they hafta chase you across the back 9... all the way to the clubhouse.
      They'll want you that bad
      Have a great weekend!
      GL

 
EXEL
3.78+0.19(+5.29%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Gilead Sciences Inc.
NasdaqGSWed, Jul 23, 2014 3:59 PM EDT